Alberto Grandi obtained his Bachelor Degree in Biological Sciences (specialization in Ecology) in 2005 and two years later his Master Degree in Biodiversity, Ecology and Evolution. From 2008 to 2015 he joined the Biotech Company Externautics SpA, located in the Toscana Life Sciences Scientific Park, where he was instrumental in the discovery and characterization of novel protein biomarkers in human cancers. While working at Externautics he obtained his PhD in Cellular Biology and Biochemistry.
In 2015 Dr. Alberto Grandi joined the Toscana Life Sciences Foundation where he has been playing a fundamental contribution to the research activities of two advanced ERC projects (OMVac and VACCIBIOME) assigned to Professor Guido Grandi (University of Trento). During the OMVac project Dr. Grandi was responsible for implementing strategies to engineer bacterial Outer Membrane Vesicles with heterologous antigens and to set-up and validate in vitro and in vivo models to test the effectiveness of vaccine prototypes against infectious diseases and cancer. Currently in the context of the VACCIBIOME project he has been working on the understanding of the anti-cancer immunological mechanisms exerted by the gut Microbiome, with the ultimate goal of finding ways to make immunotherapeutic treatments for different tumors more effective. Alberto Grandi is also a Co-founder and Head of Research of the Biotech company BiOMViS Srl, founded in 2017, located and affiliated with Toscana Life Sciences. BiOMViS has developed an innovative and unique vaccine platform base on bacterial outer membrane vesicles (OMVs) and actually, the company has in its pipeline several vaccines that have completed the pre-clinical phase and are ready to move in clinacal development. The pipeline includes vaccines against viral pathogens (SARS-CoV2 and HPV), bacterial pathogens (S.aureus and Group A Strepthococcus) and in particular, promising immunotherapeutic approches (both general and personalized) against solid tumors.